Published in Obstet Gynecol on October 01, 2002
Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG (2012) 1.57
Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis (2008) 1.35
Multicohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful information. Med Decis Making (2012) 0.79
Cost effectiveness of a program to promote screening for cervical cancer in the Vietnamese-American population. Asian Pac J Cancer Prev (2010) 0.77
Using simulation-optimization to construct screening strategies for cervical cancer. Health Care Manag Sci (2010) 0.75
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med (2007) 7.31
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 4.06
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2006) 3.39
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050. Obstet Gynecol (2009) 3.08
Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol (2006) 3.08
Histological dating of timed endometrial biopsy tissue is not related to fertility status. Fertil Steril (2004) 3.03
Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med (2003) 2.72
The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis (2003) 2.72
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.63
Absence of secretory endometrium after false-positive home urine luteinizing hormone testing. Fertil Steril (2004) 2.59
Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol (2005) 2.50
Acute myocardial infarction in pregnancy: a United States population-based study. Circulation (2006) 2.49
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Predicting the number of women who will undergo incontinence and prolapse surgery, 2010 to 2050. Am J Obstet Gynecol (2011) 2.36
Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev (2013) 2.18
Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol (2013) 2.17
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Predictors of pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2009) 1.90
Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA (2003) 1.89
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.62
Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst (2006) 1.58
The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril (2006) 1.56
Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol (2013) 1.56
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. Cancer (2010) 1.53
FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol (2005) 1.52
Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res (2006) 1.52
Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet Gynecol (2008) 1.49
Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. Am J Prev Med (2007) 1.44
Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer. Gynecol Oncol (2011) 1.44
HPV vaccines: now that they're here, how do we maximize their benefit? Contraception (2006) 1.41
A quality process study of lymph node evaluation in endometrial cancer. Int J Gynecol Pathol (2011) 1.40
Modified technique for urinary diversion with incontinent conduits. Gynecol Oncol (2002) 1.39
Cost comparison among robotic, laparoscopic, and open hysterectomy for endometrial cancer. Obstet Gynecol (2010) 1.31
Fertility patients' views about frozen embryo disposition: results of a multi-institutional U.S. survey. Fertil Steril (2008) 1.30
Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab (2010) 1.29
Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynecol (2011) 1.28
Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making (2007) 1.28
The FIBROID Registry: symptom and quality-of-life status 1 year after therapy. Obstet Gynecol (2005) 1.22
Adherence to nicotine replacement therapy among pregnant smokers. Nicotine Tob Res (2009) 1.21
Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol (2008) 1.20
Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer (2006) 1.16
Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab (2007) 1.14
Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. Cost Eff Resour Alloc (2008) 1.14
Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma. Cancer (2003) 1.13
Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol (2009) 1.12
The utility of hand-assisted laparoscopy in ovarian cancer. Gynecol Oncol (2005) 1.12
Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol (2009) 1.10
Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol Oncol (2007) 1.10
Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet Gynecol (2006) 1.09
Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Gynecol Oncol (2008) 1.09
Management of adnexal mass. Evid Rep Technol Assess (Full Rep) (2006) 1.08
Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol (2009) 1.06
Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol (2004) 1.02
Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. Cancer (2009) 1.01
Challenges and solutions for recruiting pregnant smokers into a nicotine replacement therapy trial. Nicotine Tob Res (2006) 1.01
Leiomyoma-related hospitalization and surgery: prevalence and predicted growth based on population trends. Am J Obstet Gynecol (2011) 1.00
Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. J Low Genit Tract Dis (2010) 0.99
Projecting the need for gynecologic oncologists for the next 40 years. Obstet Gynecol (2010) 0.99
Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecol Oncol (2007) 0.98
Gynecologic malignancies in women aged less than 25 years. Obstet Gynecol (2005) 0.97
Should older women have antepartum testing to prevent unexplained stillbirth? Obstet Gynecol (2004) 0.97
Bilateral and multinodular signet-ring stromal tumor of the ovary. Obstet Gynecol (2010) 0.96
Cost-effectiveness analysis of annual screening strategies for endometrial cancer. Am J Obstet Gynecol (2009) 0.96
Racial disparities in blacks with gynecologic cancers. Cancer (2007) 0.95
Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol (2013) 0.94
Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis. Gynecol Oncol (2007) 0.94
Topical advances in wound care. Gynecol Oncol (2008) 0.93
Utility scores and treatment preferences for clinical early-stage cervical cancer. Value Health (2011) 0.93
Effects of race and clinical factors on short-term outcomes of abdominal myomectomy. Obstet Gynecol (2003) 0.93
Screening for cervical cancer: a modeling study for the US Preventive Services Task Force. J Low Genit Tract Dis (2013) 0.93
The Fibroid Registry for outcomes data (FIBROID) for uterine embolization: short-term outcomes. Obstet Gynecol (2005) 0.93
High throughput, cell type-specific analysis of key proteins in human endometrial biopsies of women from fertile and infertile couples. Hum Reprod (2012) 0.91
Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet Gynecol (2006) 0.91
Smoking prevalence in early pregnancy: comparison of self-report and anonymous urine cotinine testing. J Matern Fetal Neonatal Med (2010) 0.91
Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. J Adolesc Health (2012) 0.91
Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. Cancer Res (2005) 0.90
Erythropoietin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol (2005) 0.89
Impact of a routine, opt-out HIV testing program on HIV testing and case detection in North Carolina sexually transmitted disease clinics. Sex Transm Dis (2014) 0.89
Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment. Gynecol Oncol (2011) 0.88
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. Int J Gynecol Cancer (2013) 0.88
Prioritization of patient-centered comparative effectiveness research for osteoarthritis. Ann Intern Med (2014) 0.88
A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. Gynecol Oncol (2009) 0.88
Genomic tests for ovarian cancer detection and management. Evid Rep Technol Assess (Full Rep) (2006) 0.88
Asian-Pacific Islander race independently predicts poor outcome in patients with endometrial cancer. Gynecol Oncol (2003) 0.87
Controversial topics in abnormal cervical cytology: "see and treat". Clin Obstet Gynecol (2005) 0.87
Adverse birth outcomes among nulliparous vs. multiparous women. Public Health Rep (2011) 0.87
Papillary serous adenocarcinoma of the ovary diagnosed after malignant pericardial tamponade and embolic stroke. Gynecol Oncol (2002) 0.87